146 related articles for article (PubMed ID: 32069833)
21. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
22. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
[TBL] [Abstract][Full Text] [Related]
23. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines.
Mohammadian M; Zeynali S; Azarbaijani AF; Khadem Ansari MH; Kheradmand F
Res Pharm Sci; 2017 Dec; 12(6):517-525. PubMed ID: 29204180
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
26. An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer.
Wang Q; Wang Z; Wu Y; Klinke DJ
BMC Cancer; 2020 Jan; 20(1):26. PubMed ID: 31914948
[TBL] [Abstract][Full Text] [Related]
27. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
Shin SY; Müller AK; Verma N; Lev S; Nguyen LK
PLoS Comput Biol; 2018 Jun; 14(6):e1006192. PubMed ID: 29920512
[TBL] [Abstract][Full Text] [Related]
28. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
29. Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death.
Guest ST; Kratche ZR; Irish JC; Wilson RC; Haddad R; Gray JW; Garrett-Mayer E; Ethier SP
Oncotarget; 2016 Jun; 7(24):36138-36153. PubMed ID: 27153554
[TBL] [Abstract][Full Text] [Related]
30. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
31. Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.
Davis SL; Robertson KM; Pitts TM; Tentler JJ; Bradshaw-Pierce EL; Klauck PJ; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Ecsedy JA; Arcaroli JJ; Messersmith WA; Tan AC; Eckhardt SG
Front Pharmacol; 2015; 6():120. PubMed ID: 26136684
[TBL] [Abstract][Full Text] [Related]
32. Synergistic Inhibition of Kinase Pathways Overcomes Resistance of Colorectal Cancer Spheroids to Cyclic Targeted Therapies.
Thakuri PS; Gupta M; Joshi R; Singh S; Tavana H
ACS Pharmacol Transl Sci; 2019 Aug; 2(4):275-284. PubMed ID: 32259061
[TBL] [Abstract][Full Text] [Related]
33. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Eustace AJ; Crown J; Clynes M; O'Donovan N
J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
[TBL] [Abstract][Full Text] [Related]
35. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
36. Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002.
Goltsov A; Tashkandi G; Langdon SP; Harrison DJ; Bown JL
Eur J Pharm Sci; 2017 Jan; 97():170-181. PubMed ID: 27832967
[TBL] [Abstract][Full Text] [Related]
37. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
38. In silico drug combination discovery for personalized cancer therapy.
Jeon M; Kim S; Park S; Lee H; Kang J
BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
[TBL] [Abstract][Full Text] [Related]
39. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
40. Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.
Yadav B; Wennerberg K; Aittokallio T; Tang J
Comput Struct Biotechnol J; 2015; 13():504-13. PubMed ID: 26949479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
